Clostridium difficile infection in hospitalized patients at a Czech tertiary center: Analysis of epidemiology, clinical features, and risk factors of fulminant course

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 8, 2014, Pages 880-887

  Balihar, Karel ^a   Kozak, Filip ^a   Kozeluhova, Jana ^a   Hejda, Vaclav ^a   Fremundova, Lucie ^a   Krcma, Michal ^a   Geigerova, Lenka ^a   Bergerova, Tamara ^a   Matejovic, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

antibiotic consumption; Clostridium difficile infection; incidence; mortality; risk factors

Indexed keywords

ALBUMIN; CREATININE; HISTAMINE H2 RECEPTOR ANTAGONIST; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CZECH REPUBLIC; DRUG USE; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; TERTIARY HEALTH CARE; CROSS INFECTION; DRUG UTILIZATION; EARLY DIAGNOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HOSPITALIZATION; MIDDLE AGED; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; CZECH REPUBLIC; DRUG UTILIZATION; EARLY DIAGNOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84904044730     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000139     Document Type: Article

References (26)

1. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142:624-631, discussion 631.
2. Kuijper EJ, Coignard B, Tull P. ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (Suppl 6):2-18.
3. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73.
4. Bhangu S, Bhangu A, Nightingale P, Michael A. Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. Colorectal Dis 2010; 12:241-246.
5. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15:415-422.
6. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144:433-439, discussion 439-440.
7. Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009; 29:635-642.
8. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-1084.
9. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007; 35:300-307.
10. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficileassociated diarrhoea. Aliment Pharmacol Ther 2006; 24:613-619.
11. Vesta KS, Wells PG, Gentry CA, Stipek WJ. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control 2005; 33:469-472.
12. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino JE, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 2010; 31:1030-1037.
13. Debast SB, Bauer MP, Kuijper EJ. Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2013; 20 (Suppl 2):1-26.
14. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. Assessing illness severity: does clinical judgment work? J Chronic Dis 1986; 39:439-452.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
16. World Health Organization (WHO); Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: Norwegian Institute of Public Health; 2012.
17. Alcala L, Martín A, Marín M, Sánchez-Somolinos M, Catalán P, Peláez T, Bouza E; Spanish Clostridium difficile Study Group. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect 2012; 18:E204-E213.
18. Ahmetagic S, Salkic N, Ahmetagic A, Custovic A, Tihic N, Smajlovic J, Porobic-Jahic H. Clostridium difficile infection in hospitalized patients at University Clinical Center Tuzla, Bosnia and Herzegovina: a 4 year experience. Mater Sociomed 2013; 25:153-157.
19. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298-304.
20. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-307.
21. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171:51-58.
22. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47:1620-1626.
23. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
24. Ponce J, Esplugues JV. Rationalizing the use of PPIs: an unresolved matter. Rev Esp Enferm Dig 2013; 105:121-124.
25. Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45 (Suppl 2):S112-S121.
26. Ludlam H, Brown N, Sule O, Redpath C, Coni N, Owen G. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing 1999; 28:578-580.